WO2003053436A1 - Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma - Google Patents

Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma Download PDF

Info

Publication number
WO2003053436A1
WO2003053436A1 PCT/US2002/039316 US0239316W WO03053436A1 WO 2003053436 A1 WO2003053436 A1 WO 2003053436A1 US 0239316 W US0239316 W US 0239316W WO 03053436 A1 WO03053436 A1 WO 03053436A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
compound
alkyl
difuran
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/039316
Other languages
English (en)
French (fr)
Inventor
Zixia Feng
Mark R. Hellberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Priority to US10/525,410 priority Critical patent/US7208512B2/en
Priority to BR0215172-3A priority patent/BR0215172A/pt
Priority to EP02790063A priority patent/EP1455780A4/en
Priority to JP2003554193A priority patent/JP2005513103A/ja
Priority to AU2002353088A priority patent/AU2002353088B2/en
Priority to CA002469904A priority patent/CA2469904A1/en
Priority to MXPA04006029A priority patent/MXPA04006029A/es
Priority to KR10-2004-7009781A priority patent/KR20040068315A/ko
Publication of WO2003053436A1 publication Critical patent/WO2003053436A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention provides novel compounds,
  • compositions and methods for treating glaucoma, lowering intraocular pressure are provided.
  • glaucoma or functionally distinct types of glaucoma are typically characterized by elevated IOP,
  • hypertension is a condition wherein intraocular pressure is elevated but no apparent loss of
  • tension or low tension glaucoma patients can also benefit from agents that lower and
  • Such therapies are in general administered by one of two possible routes, topically (direct
  • Serotonin (5-hydroxy tryptamine; 5HT) is an endogenous biogenic amine with a
  • 5HT is known to interact with at least seven major 5HT receptors ( ⁇ HT j - 5HT 7 ),
  • AC adenylyl cyclase
  • 5HT 4 , 5HT 6 , and 5HT 7 receptors are positively coupled to AC and thus
  • the 5HT 2 family are positively coupled to phospholipase C (PLC) and thus generate PLC
  • inositol phosphates and mobilize intracellular calcium when activated to mediate the
  • the 5HT 3 receptor is unique in that it couples to an ion channel which
  • CNS central nervous system
  • ⁇ 2 adrenoceptor agonists are also known for their
  • the present invention for lowering IOP and providing neuiOprotection. More specifically, the present invention
  • A, B and D are independently chosen from either N or C, with the provision that
  • A, B or D is N; E is C or N; R is H or C M alkyl; R 2 and R 3 are independently
  • the present invention provides compositions containing the
  • compositions are most preferably in the form of topical
  • the compounds of the invention may be
  • compositions of the invention are preferably formulated as topical ophthalmic
  • the present invention further provides a method of lowering intraocular pressure
  • composition can be any composition having the structure as described above.
  • the composition can be any composition having the structure as described above.
  • the composition can be any composition having the structure as described above.
  • the composition can be any composition having the structure as described above.
  • the composition can be any composition having the structure as described above.
  • the composition can be any composition having the structure as described above.
  • the composition can be any composition having the structure as described above.
  • the composition can be any composition having the structure as described above.
  • the eye e.g., topically, intracamerally, or via an implant.
  • the compounds provide neuroprotective activity and are useful for
  • U.S. Patent 5,494,928 discloses certain 2-(indol-l-yl)-ethylamine
  • U.S. Patent 5,874,477 discloses a method for treating malaria using 5-HT 2A/2C agonists.
  • U.S. Patent 5,902,815 discloses the use of 5-HT 2A agonists to prevent adverse effects of
  • WO 98/31354 A2 discloses 5-HT 2B agonists for the
  • Serotonergic 5-HT 1A agonists have been reported as being neuroprotective in
  • 5-HT 1A agonist reduces IOP in rabbits (Osborne et al. 1996). Wang et al. disclose that 5-HT 1A agonist
  • anti-migraine compounds are 5-HT 1B D E F agonists, e.g., sumatriptan and
  • the present invention provides compounds possessing ⁇ 2 adrenoceptor agonist
  • A, B and D are independently chosen from ether N, C, with the provision that at
  • A, B or D is N; E is C or N; R is H, C M alkyl; R 2 is H, C,. 3 alkyl, or C 2 _ 3
  • R 3 is H, C 1 _ 3 alkyl, or C 2 . 3 alkenyl; or R 2 and R 3 taken together can form a 5 or 6
  • X is chosen from hydrogen, halogen, C ] . 4 alkyl, CF 3 ; the dashed bond
  • ES 323985 discusses that oxymetazoline is currently used for nasal de-congestion
  • oxymetazoline for lowering IOP and ocular neuroprotection. Moreover, oxymetazoline is
  • This invention contemplates all enantiomers, diastereomers and, mixtures thereof.
  • this definition includes straight chain, branched chain, and cyclic alkyl or (cyclic
  • halogen which means fluorine, chlorine, bromine, or iodine, would indicate that the unit
  • halogen atoms which may be
  • the compounds of the invention can be administered systemically or locally to the
  • ophthalmologically acceptable preservatives may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity
  • Ophthalmic solution formulations may be
  • the ophthalmic solution may include an ophthalmologically acceptable
  • an agent ' to increase viscosity such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose,
  • Gelling agents can also be used, including, but not limited to, gellan and
  • ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil,
  • liquid lanolin or white petrolatum.
  • Sterile ophthalmic gel formulations may be prepared
  • the compounds of the invention are preferably formulated as topical ophthalmic
  • formulations would be delivered to the surface of the eye 1 to 4 times per day according to
  • the compounds can also be used in combination with other IOP lowering agents,
  • ⁇ -blockers such as, but not limited to, ⁇ -blockers, prostaglandins, carbonic anhydrase inhibitors, and
  • the compounds can also be used in combination with other agents useful for the
  • treating glaucoma such as, but not limited to, calcium channel blockers and NMDA
  • Examples of the compounds of this invention may be prepared by the synthetic
  • the halogenated ether 2 is brominated
  • solvent such as dioxane or tetrahydrofuran maintained at a temperature of -40 to 0° C.
  • the alcohol is converted to the chloride 7 by treatment with thionyl chloride in the
  • nitrile 8 is formed by
  • DDQ dicyano-l,4-benzoquinone
  • Step B l,4-Bis(2-chloroethoxy)-2,5-dibromobenzene
  • Step D 4-Formyl-2,3,6,7-tetrahydrobenzol[l,2-b;4,5-b']difuran
  • Tin(IN) chloride (11.7 ml, O.lmol) was added through a syringe to a solution of
  • Step F 4-Chloromethyl-2,3,6,7-tetrahrdrobenzol[l,2-b;4,5-b']difuran
  • Step H 4-Acetonitrile-8-bromo-2,3 . 6,7-tetrahrdrobenzol[l,2-b;4,5-b'] difuran
  • Step I 4-Acetonitrile-8-bromo-[l,2-b;4,5-b']difuran
  • Step K 2-(8-Bromo-benzo-[l,2-b;4,5-b']difuran- 4-yl)imidazoline
  • brain 5-HT 2 receptors is determined as described below with minor modification of the
  • DMEM Dulbecco's modified Eagle medium
  • test agent or solvent as the control
  • Serotonin (5-HT) is used as a positive
  • control (standard) agonist compound and the efficacy of test compounds is compared to
  • ⁇ 1 ⁇ M are considered full agonists if their efficacy is > 80% of that of 5-HT.
  • Intraocular pressure can be determined with an Alcon Pneumatonometer
  • test compound is instilled in one
  • Ligand binding studies can also be run using membrane preparations from calf and
  • rat brain local source
  • human cortex membranes Specific brain regions were
  • Rat hippocampal membranes were homogenized in 25
  • pellet was re-suspended in homogenization buffer at a protein concentration of
  • TCA trichloroacetic acid
  • Cyclic AMP production was calculated as the ratio [ 3 H]cAMP/([ 3 H]cAMP +
  • Example 8 Alpha-2 Adrenergic Receptor Assay Methods Cell culture.
  • HT29 human clonic adenocarcinoma cells For the alpha-2A assays, HT29 human clonic adenocarcinoma cells
  • Cyclic AMP functional assays Confluent cultures of HT29 cells were washed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2002/039316 2001-12-20 2002-12-09 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma Ceased WO2003053436A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/525,410 US7208512B2 (en) 2001-12-20 2002-12-09 Benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
BR0215172-3A BR0215172A (pt) 2001-12-20 2002-12-09 Derivados de benzodifuranimidazolina e benzofuranimidazolina e seu emprego para o tratamento de glaucoma
EP02790063A EP1455780A4 (en) 2001-12-20 2002-12-09 NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
JP2003554193A JP2005513103A (ja) 2001-12-20 2002-12-09 緑内障の処置のための新規ベンゾジフランイミダゾリンおよびベンゾフランイミダゾリン誘導体ならびにそれらの使用
AU2002353088A AU2002353088B2 (en) 2001-12-20 2002-12-09 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
CA002469904A CA2469904A1 (en) 2001-12-20 2002-12-09 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
MXPA04006029A MXPA04006029A (es) 2001-12-20 2002-12-09 Derivados novedosos de benzofuranimidazolina y benzodifuranimidazolina y su uso para el tratamiento de glaucoma.
KR10-2004-7009781A KR20040068315A (ko) 2001-12-20 2002-12-09 벤조디푸란이미다졸린 및 벤조푸란이미다졸린 유도체 및녹내장 치료를 위한 이들의 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34337801P 2001-12-20 2001-12-20
US60/343,378 2001-12-20

Publications (1)

Publication Number Publication Date
WO2003053436A1 true WO2003053436A1 (en) 2003-07-03

Family

ID=23345873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039316 Ceased WO2003053436A1 (en) 2001-12-20 2002-12-09 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma

Country Status (13)

Country Link
US (1) US7208512B2 (enExample)
EP (1) EP1455780A4 (enExample)
JP (1) JP2005513103A (enExample)
KR (1) KR20040068315A (enExample)
CN (1) CN1268334C (enExample)
AR (1) AR037880A1 (enExample)
AU (1) AU2002353088B2 (enExample)
BR (1) BR0215172A (enExample)
CA (1) CA2469904A1 (enExample)
MX (1) MXPA04006029A (enExample)
TW (1) TW593302B (enExample)
WO (1) WO2003053436A1 (enExample)
ZA (1) ZA200404473B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7060704B2 (en) 1998-05-19 2006-06-13 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7208512B2 (en) 2001-12-20 2007-04-24 Alcon, Inc. Benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7396856B2 (en) 2002-12-13 2008-07-08 Alcon, Inc. Benzopyran analogs and their use for the treatment of glaucoma
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036975A1 (en) * 1990-02-27 1991-08-28 Marc Lang Benzofurans

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES323985A1 (es) 1966-02-26 1966-12-16 Blade Pique Juan Procedimiento para la obtenciën de derivados del imidazol
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
EP1293525A3 (en) 1990-06-26 2005-09-07 AorTech Biomaterials Pty Ltd Polyurethane or polyurethan-urea elastomeric compositions
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
JPH06508354A (ja) * 1991-06-21 1994-09-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー トリプタミン類似体、その合成法およびその５−ｈｔ↓１様または５−ｈｔ↓２受容体作用物質としての使用
GB9216380D0 (en) 1992-07-31 1992-09-16 Glaxo Group Ltd Medicaments
US5290781A (en) * 1993-01-05 1994-03-01 Iolab Corporation Ketaneserinol as an agent to reduce intraocular pressure
US5891131A (en) * 1993-02-01 1999-04-06 Arizona Board Of Regents Method and apparatus for automated simulation and design of corneal refractive procedures
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5538974A (en) * 1994-01-27 1996-07-23 Senju Pharamceutical Co., Ltd. Ophthalmic composition for lowering intraocular pressure
ATE166227T1 (de) * 1994-03-18 1998-06-15 Senju Pharma Co Sarpogrelat enthaltende opthalmologische zubereitungen zur senkung des intraokularen druckes
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
US5874477A (en) * 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
US5998467A (en) 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
WO1997035579A1 (en) 1996-03-27 1997-10-02 Merck & Co., Inc. A method for inhibiting clot formation
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
AU4249297A (en) 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
WO1999059499A2 (en) 1998-05-19 1999-11-25 Alcon Laboratories, Inc. Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
AU755119B2 (en) 1998-09-18 2002-12-05 Alcon Laboratories, Inc. Serotonergic 5HT2 agonists for treating glaucoma
EA200100671A1 (ru) 1998-12-17 2001-12-24 Американ Хоум Продактс Корпорейшн ПРОИЗВОДНЫЕ 2,3,4,4a-ТЕТРАГИДРО-1H-ПИРАЗИНО [1,2a]ХИНОКСАЛИН-5(6H)-ОНА, ЯВЛЯЮЩИЕСЯ АГОНИСТАМИ 5HT2C
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
WO2001040183A1 (en) 1999-12-03 2001-06-07 Alcon Universal Ltd. 1-aminoalkyl-1h-indoles for treating glaucoma
WO2001070705A1 (en) * 2000-03-17 2001-09-27 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
WO2001070223A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
WO2001070701A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
US6806285B1 (en) * 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
TR200400424T4 (tr) 2000-03-17 2004-03-22 Alcon, Inc. IOP'nin kontrolü ve glokom tedavisi için 5HT2 agonistleri
AU2001216072A1 (en) 2000-03-17 2001-10-03 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
DE60005566T2 (de) 2000-03-17 2004-07-29 Alcon, Inc. Pyranoindole zur glaukombehandlung
JP2004532887A (ja) 2001-06-01 2004-10-28 アルコン，インコーポレイテッド 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用
MXPA03010806A (es) 2001-06-01 2004-11-22 Alcon Inc Nuevos analogos de arilaminopropano y su uso para el tratamiento de glaucoma.
WO2002098350A2 (en) 2001-06-01 2002-12-12 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
WO2003051352A1 (en) 2001-12-14 2003-06-26 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
AU2002364711A1 (en) 2001-12-14 2003-06-30 Alcon, Inc. Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
WO2004019874A2 (en) 2002-08-30 2004-03-11 Alcon, Inc. Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
JP2006506355A (ja) 2002-09-24 2006-02-23 ヴァージニア コモンウェルス ユニバーシティ β−ヒドロキシフェニルアルキルアミンおよびその緑内障治療への使用
EP1581209A4 (en) 2002-12-13 2009-03-11 Alcon Inc NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
US20060052613A1 (en) 2002-12-23 2006-03-09 Pete Delgado 1-alkyl-3-aminoindazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036975A1 (en) * 1990-02-27 1991-08-28 Marc Lang Benzofurans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1455780A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060704B2 (en) 1998-05-19 2006-06-13 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US7285553B2 (en) 1998-05-19 2007-10-23 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US7208512B2 (en) 2001-12-20 2007-04-24 Alcon, Inc. Benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
US7396856B2 (en) 2002-12-13 2008-07-08 Alcon, Inc. Benzopyran analogs and their use for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7268131B2 (en) 2003-12-15 2007-09-11 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7439262B1 (en) 2003-12-15 2008-10-21 Alcon, Inc. Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Also Published As

Publication number Publication date
EP1455780A4 (en) 2005-04-06
MXPA04006029A (es) 2004-09-27
BR0215172A (pt) 2004-10-19
AU2002353088B2 (en) 2006-09-21
TW200301257A (en) 2003-07-01
US20060009503A1 (en) 2006-01-12
US7208512B2 (en) 2007-04-24
CN1606441A (zh) 2005-04-13
AU2002353088A1 (en) 2003-07-09
KR20040068315A (ko) 2004-07-30
CN1268334C (zh) 2006-08-09
TW593302B (en) 2004-06-21
AR037880A1 (es) 2004-12-09
JP2005513103A (ja) 2005-05-12
ZA200404473B (en) 2005-06-07
CA2469904A1 (en) 2003-07-03
EP1455780A1 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
US6884816B2 (en) Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US6960608B2 (en) Fused indazoles and indoles and their use for the treatment of glaucoma
AU2002353088B2 (en) Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
US20040110791A1 (en) Novel arylaminopropane analogues and their use for the treatment of glaucoma
MXPA02008825A (es) Derivados 5-hidroxi indazol para tratamiento de glaucoma.
US7396856B2 (en) Benzopyran analogs and their use for the treatment of glaucoma
US20050171190A1 (en) Substituted 5-chroman-5-YL-ethylamine compounds and their use for the treatment of glaucoma
AU2001216034B2 (en) Pyranoindoles for treating glaucoma
US7268131B2 (en) Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7012090B1 (en) Pyranoindoles for treating glaucoma
US7129257B1 (en) Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7439262B1 (en) Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma
HK1050897B (en) Pyranoindoles for treating glaucoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002353088

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/04473

Country of ref document: ZA

Ref document number: 200404473

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002790063

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2469904

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003554193

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/006029

Country of ref document: MX

Ref document number: 20028254643

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020047009781

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002790063

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10525410

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2006009503

Country of ref document: US

Kind code of ref document: A1

WWP Wipo information: published in national office

Ref document number: 10525410

Country of ref document: US